These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16840887)

  • 1. [Medical management of patients with stable coronary artery disease in France in 2004. Data from the Mutualité Sociale Agricole].
    Jeantet M; Gosselin S; Lefrand E; Hunold H; Vanbockstael V; Bertrand D; Danchin N
    Presse Med; 2006; 35(7-8):1123-30. PubMed ID: 16840887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
    Danchin N; Hanania G; Grenier O; Vaur L; Amelineau E; Guéret P; Blanchard D; Ferrières J; Genès N; Lablanche JM; Cantet C; Cambou JP
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):1-6. PubMed ID: 12710288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the use of hypolipidemic agents (HAs), mainly statins, in elderly subjects aged 80 years and more in Burgundy: analysis of 13,211 patients.
    Manckoundia P; Lorenzini M; Disson-Dautriche A; Petit JM; Lorcerie B; Debost E; Menu D; Pfitzenmeyer P
    Arch Gerontol Geriatr; 2012; 55(1):101-5. PubMed ID: 21868109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease.
    Meurice T; Tricot O; Lemesle G; Deneve M; Lejeune P; Biausque F; Cordier C; Savoye C; Hennebert O; Taghipour K; Sivery B; Pruvost P; Alaoui M; Carpentier L; Segrestin B; Lamblin N; Bauters C
    Arch Cardiovasc Dis; 2015; 108(6-7):340-6. PubMed ID: 25858539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
    Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A; Kruger A; Kutty R; Lanas F; Lisheng L; Wei L; Lopez-Jaramillo P; Oguz A; Rahman O; Swidan H; Yusoff K; Zatonski W; Rosengren A; Teo KK;
    Lancet; 2011 Oct; 378(9798):1231-43. PubMed ID: 21872920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice].
    Philippe F; Cambou JP; Danchin N; Thomas D
    Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S30-6. PubMed ID: 16411649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
    Bezin J; Pariente A; Lassalle R; Dureau-Pournin C; Abouelfath A; Robinson P; Moore N; Droz-Perroteau C; Fourrier-Reglat A
    Eur J Clin Pharmacol; 2014 Apr; 70(4):429-36. PubMed ID: 24271648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry.
    Danchin N; Cambou JP; Hanania G; Kadri Z; Genès N; Lablanche JM; Blanchard D; Vaur L; Clerson P; Guéret P;
    Am Heart J; 2005 Dec; 150(6):1147-53. PubMed ID: 16338251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home.
    Joseph J; Koka M; Aronow WS
    J Am Med Dir Assoc; 2008 Feb; 9(2):124-7. PubMed ID: 18261706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals.
    Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS
    QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex Differences in Cardiac Medication Use Post-Catheterization in Patients Undergoing Coronary Angiography for Stable Angina with Nonobstructive Coronary Artery Disease.
    Galway S; Adatia F; Grubisic M; Lee M; Daniele P; Humphries KH; Sedlak TL
    J Womens Health (Larchmt); 2017 Sep; 26(9):976-983. PubMed ID: 28384013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey].
    Jullien G; Mosnier M; Danchin N
    Ann Cardiol Angeiol (Paris); 2005 Aug; 54(4):184-9. PubMed ID: 16104618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis at 6 months for coronary and cerebrovascular patients: impact of antiplatelet agents and statins: results from the Prevenir III study.
    Ferrières J; Cambou JP; Cantet C; Guize L
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):55-61. PubMed ID: 16552472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
    Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention of coronary heart disease in older patients after the national service framework: population based study.
    Ramsay SE; Whincup PH; Lawlor DA; Papacosta O; Lennon LT; Thomas MC; Ebrahim S; Morris RW
    BMJ; 2006 Jan; 332(7534):144-5. PubMed ID: 16401630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
    Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The UK National Health Service: delivering equitable treatment across the spectrum of coronary disease.
    Hawkins NM; Scholes S; Bajekal M; Love H; O'Flaherty M; Raine R; Capewell S
    Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):208-16. PubMed ID: 23481523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC; Erskine N; McManus DD; Lessard D; Gore JM; Yarzebski J; Goldberg RJ
    Am J Cardiol; 2016 Dec; 118(12):1792-1797. PubMed ID: 27743577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical management of stable coronary artery disease.
    Pflieger M; Winslow BT; Mills K; Dauber IM
    Am Fam Physician; 2011 Apr; 83(7):819-26. PubMed ID: 21524048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.